INT8579

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 1990
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 13
Total Number 27
Disease Relevance 35.89
Pain Relevance 7.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa1) transport (Apoa1) extracellular space (Apoa1)
extracellular region (Apoa1) nucleus (Apoa1) enzyme binding (Apoa1)
Anatomy Link Frequency
Blood 1
liver 1
endothelial cells 1
leucocyte 1
duct 1
Apoa1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 720 99.84 Very High Very High Very High
rheumatoid arthritis 255 99.84 Very High Very High Very High
Chronic pancreatitis 1 98.84 Very High Very High Very High
Sciatic nerve 15 97.20 Very High Very High Very High
Inflammation 144 96.88 Very High Very High Very High
alcohol 16 93.04 High High
Restless leg syndrome 1 92.20 High High
Bile 2 92.04 High High
cytokine 121 91.60 High High
lidocaine 1 91.44 High High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 304 100.00 Very High Very High Very High
Hepatotoxicity 5 99.92 Very High Very High Very High
Demyelinating Disease 885 99.84 Very High Very High Very High
Systemic Lupus Erythematosus 285 99.84 Very High Very High Very High
Rheumatoid Arthritis 255 99.84 Very High Very High Very High
Encephalitis 75 99.46 Very High Very High Very High
Syndrome 210 99.16 Very High Very High Very High
Pancreatitis 2 98.84 Very High Very High Very High
Pancreatic Cancer 4 98.40 Very High Very High Very High
Injury 31 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Similar to the Shore ea al, our research showed increased serum apoA-I levels in MS patients and other autoimmune demyelinating disease (CIS, GBS) whether male and female patients.
Spec (whether) Gene_expression (levels) of apoA-I associated with multiple sclerosis, syndrome and demyelinating disease
1) Confidence 0.76 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.10 Pain Relevance 0.61
There was no significant different serum apoA-I levels among patients with CIS (1.422 ± 0.091 g/L; P = 0.177), GBS (1.260 ± 0.093 g/L; P = 0.978), viral encephalitis(1.062 ± 0.080 g/L;P = 0.067) and healthy subjects (1.112 ± 0.070 g/L; P = 0.142).
Gene_expression (levels) of apoA-I associated with syndrome and encephalitis
2) Confidence 0.76 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.83 Pain Relevance 0.43
Serum apoA-I levels in RA and SLE patients (P = 0.002) significantly lower than healthy control.
Gene_expression (levels) of apoA-I associated with rheumatoid arthritis and systemic lupus erythematosus
3) Confidence 0.76 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.32 Pain Relevance 0.23
Therefore, a large number of serum apoA-I synthesized by liver will be albe to meet the remyelination during acute phase of MS.
Gene_expression (synthesized) of apoA-I in liver associated with multiple sclerosis
4) Confidence 0.76 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.11 Pain Relevance 0.49
We found significantly higher serum apoA-I levels in MS (1.392 ± 0.047 g/L) and other autoimmune demyelinating diseases (GBS, CIS) than healthy subjects (1.179 ± 0.047 g/L), RA (1.035 ± 0.061 g/L) and SLE patients(1.179 ± 0.047 g/L).
Gene_expression (levels) of apoA-I associated with multiple sclerosis, syndrome, rheumatoid arthritis, systemic lupus erythematosus and demyelinating disease
5) Confidence 0.76 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.21 Pain Relevance 0.19
For male patients (Table 2), male MS patients (1.263 ± 0.075 g/L) had significantly higher serum apoA-I levels than male RA patients (0.963 ± 0.102 g/L; P = 0.000), male SLE patients (0.979 ± 0.106 g/L; P = 0.000) and male healthy subjects(1.112 ± 0.070 g/L; P = 0.001) (Figure 2).
Gene_expression (levels) of apoA-I associated with multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus
6) Confidence 0.66 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.85 Pain Relevance 0.38
Female patients with viral encephalitis (1.243 ± 0.064 g/L) showed lower serum apoA-I levels than MS patients (P = 0.002).
Gene_expression (levels) of apoA-I associated with multiple sclerosis and encephalitis
7) Confidence 0.66 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.72 Pain Relevance 0.34
The results showed that serum apoA-I levels was much higher in female MS patients (1.523 ± 0.082 g/L) and female RA patients (1.120 ± 0.042 g/L) than the corresponding male MS patients (1.262 ± 0.087 g/L; P = 120.033) and male RA patients (0.948 ± 0.049 g/L; P = 120.012) (Figure 3).


Gene_expression (levels) of apoA-I associated with multiple sclerosis and rheumatoid arthritis
8) Confidence 0.66 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.63 Pain Relevance 0.43
We selected the patients with viral encephalitis in order to compare serum apoA-I levels between the those patients and MS patients.
Gene_expression (levels) of apoA-I associated with multiple sclerosis and encephalitis
9) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.46 Pain Relevance 0.58
For women, healthy control (1.230 ± 0.062 g/L) had significantly higher serum apoA-I levels than SLE patients (0.897 ± 0.068 g/L; P < 0.001), but significantly lower than female MS patients (1.516 ± 0.057 g/L; P = 0.001).
Gene_expression (levels) of apoA-I associated with multiple sclerosis and systemic lupus erythematosus
10) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.53 Pain Relevance 0.32
Meanwhile, we proved the highest serum apoA-I levels in MS patients and the lowest serum apoA-I levels in SLE patients.
Gene_expression (levels) of apoA-I associated with multiple sclerosis and systemic lupus erythematosus
11) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Abstract Doc Link PMC2860353 Disease Relevance 1.81 Pain Relevance 0.38
In the presentation, MS patients and RA as well as SLE patients were compared, because research had shown that low serum levels of apoA-I in RA and SLE patients [15,17].
Gene_expression (levels) of apoA-I associated with multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus
12) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 2.37 Pain Relevance 0.62
In the presentation we performed a study on serum apoA-I levels in the patients with MS.
Gene_expression (levels) of apoA-I associated with multiple sclerosis
13) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Abstract Doc Link PMC2860353 Disease Relevance 1.70 Pain Relevance 0.36
Meanwhile, we proved the highest serum apoA-I levels in MS patients and the lowest serum apoA-I levels in SLE patients.
Gene_expression (levels) of apoA-I associated with multiple sclerosis and systemic lupus erythematosus
14) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Abstract Doc Link PMC2860353 Disease Relevance 1.84 Pain Relevance 0.39
Consisted with above findings, in our study, serum apoA-I levels in RA and SLE patients were significantly lower than healthy subjects.
Gene_expression (levels) of apoA-I associated with rheumatoid arthritis and systemic lupus erythematosus
15) Confidence 0.59 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.72 Pain Relevance 0.62
Apo AI levels fell in both groups to day 5, but then began to increase in the group with good hepatic function, a highly significant (P < 0.001) positive correlation being found with the results of the MEGX test on post-transplant days 7, 10 and 14.
Gene_expression (levels) of Apo AI
16) Confidence 0.24 Published 1995 Journal Eur. J. Clin. Invest. Section Abstract Doc Link 7556366 Disease Relevance 0.33 Pain Relevance 0.09
The levels of total cholesterol, triglyceride, LDL-C, HDL-C, apolipoprotein A1 and apolipoprotein B in the serum were measured in a selected series of 100 CAD patients (77 men and 23 women) who underwent coronary angiography and 141 non-CAD controls.
Gene_expression (levels) of apolipoprotein A1 associated with coronary artery disease and disorder of lipid metabolism
17) Confidence 0.16 Published 1990 Journal Zhonghua Xin Xue Guan Bing Za Zhi Section Abstract Doc Link 2128269 Disease Relevance 1.33 Pain Relevance 0.07
Lovastatin and niacin in low doses used in the present study resulted in a significant decline in LDL cholesterol, triglycerides, and lp(a) along with an increase in HDL cholesterol and apoA1/apoB ratio.
Gene_expression (ratio) of apoA1 associated with disorder of lipid metabolism
18) Confidence 0.12 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 1.32 Pain Relevance 0.10
They hypothesized that this may be facilitated by the interaction of apolipoprotein A-I, present on the surface of the NPs, with the scavenger receptor class B, type I, the prime receptor for high density lipoprotein/apoA-I that is expressed on brain capillary endothelial cells (BCEC) [81].
Gene_expression (expressed) of apoA-I in endothelial cells associated with disorder of lipid metabolism
19) Confidence 0.11 Published 2010 Journal Part Fibre Toxicol Section Body Doc Link PMC2847536 Disease Relevance 0.47 Pain Relevance 0
At the end of weeks 4, 12, and 24, statistically significant changes were observed in the levels of LDL cholesterol, HDL cholesterol, triglycerides, apoA1/apoB ratio, and lp(a).
Gene_expression (levels) of apoA1 associated with disorder of lipid metabolism
20) Confidence 0.10 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993969 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox